Document is current
Any future updates will be listed below
-
Authors
- License Information
-
More Information
Article History
Received: 23 October 2024
Revised: 11 March 2025
Accepted: 24 March 2025
First Online: 10 April 2025
Competing interests
: At the time of submission, all authors were employees of Teladoc Health and received stock as a part of compensation. At the time of resubmission, Robert Hsu and Tejaswi Kompala were affiliated with Teladoc Health. No dedicated internal or external funding was provided. The company had no role in the article’s conceptualization, writing, or decision to submit. Robert Hsu reports stock in Novo Nordisk, Eli Lilly, Hims & Hers Health, and LifeMD. Tejaswi Kompala reports prior one-time consultation for Eli Lilly.
